pai12241-sup-0001-FigS1-TableS1-S4-AppendixS1.docWord document422K

Figure S1. Scatter plots of the cumulative dose of metacholine causing at least 20% reduction in lung function (PD20) for the phenotypes within the asthma comorbidity approach.

Figure S2. The influx, outflux and also relapse (*) respectively of atopic dermatitis (AD) (left) from 2-10 and 10-16 years are described with arrows, with the corresponding influx from 10-16 years given for allergic rhinitis (AR).

Table S1. Definitions of the outcomes in the present study.

Table S2. Associations between the asthma phenotypes stratified for reported use of inhaled corticosteroids (ICS) within the last 12 months and 14 days, respectively.

Table S3. Characteristics and comparisons of subjects with asthma and allergic sensitisation (allergic asthma) and asthma without allergic sensitisation, in terms of forced expiratory volume in 1 s, exhaled nitric oxide (FENO) og metacholine challenge test (PD20).

Table S4. Prevalences of asthma, atopic diseases and allergic sensitisation at 2, 10 and 16 years of age are given for all subjects in table E2A, and by girls and boys in table E2B with significant sex difference given by *.

Table S5. The association at 16 years of age between the allergic diseases allergic rhinitis (AR) and atopic dermatitis (AD) with lung function by FEV1%, BHR and exhaled nitric oxide (PD20 and FENO, respectively) are given for the 322 subjects who never had recurrent bronchial obstruction (rBO) and/or asthma (reference group) in table E4A and for the 121 subjects with asthma in remission after 10 years of age. Due to small numbers in the rBO/asthma remission group, p-values are not presented.

Appendix S1. Methods.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.